R. P. Allen, Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: Updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria-history, rationale, description, and significance, Sleep Med, vol.15, pp.860-873, 2014.

R. P. Allen, Restless legs syndrome prevalence and impact: Rest general population study, Arch. Intern. Med, vol.165, pp.1286-1292, 2005.

J. Montplaisir, Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: A study of 133 patients diagnosed with new standard criteria, Mov. Disord, vol.12, pp.61-65, 1997.

Y. Dauvilliers and J. Winkelmann, Restless legs syndrome: Update on pathogenesis, Curr. Opin. Pulm. Med, vol.19, pp.594-600, 2013.

C. Trenkwalder, Comorbidities, treatment, and pathophysiology in restless legs syndrome, Lancet Neurol, vol.17, pp.994-1005, 2018.

B. Schormair, Identification of novel risk loci for restless legs syndrome in genome-wide association studies in individuals of European ancestry: A meta-analysis, Lancet Neurol, vol.16, pp.898-907, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01832985

J. R. Connor, S. M. Patton, K. Oexle, and R. P. Allen, Iron and restless legs syndrome: Treatment, genetics and pathophysiology, Sleep Med, vol.31, pp.61-70, 2017.

D. A. Lipschitz, J. D. Cook, and C. A. Finch, A clinical evaluation of serum ferritin as an index of iron stores, N. Engl. J. Med, vol.290, pp.1213-1216, 1974.

Y. Dauvilliers, Association between serum hepcidin level and restless legs syndrome, Mov. Disord, vol.33, pp.618-627, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01842236

N. Lammers, Are serum ferritin and transferrin saturation risk markers for restless legs syndrome in young adults? Longitudinal and cross-sectional data from the Western Australian Pregnancy Cohort (Raine) Study, J. Sleep Res, vol.28, p.12741, 2019.

M. Didriksen, Prevalence of restless legs syndrome and associated factors in an otherwise healthy population: Results from the Danish Blood Donor Study, Sleep Med, vol.36, pp.55-61, 2017.

B. Benediktsdottir, Prevalence of restless legs syndrome among adults in Iceland and Sweden: Lung function, comorbidity, ferritin, biomarkers and quality of life, Sleep Med, vol.11, pp.1043-1048, 2010.

K. Berger, Iron metabolism and the risk of Restless Legs Syndrome in an elderly general population-The MEMO-Study, J. Neurol, vol.249, pp.1195-1199, 2002.

B. Frauscher, The severity range of restless legs syndrome (RLS) and augmentation in a prospective patient cohort: Association with ferritin levels, Sleep Med, vol.10, pp.611-615, 2009.

S. Leu-semenescu, C. Petiau, C. Charley-monaca, and Y. Dauvilliers, French consensus: Augmentation syndrome in restless legs syndrome, Rev. Neurol, vol.174, pp.532-539, 2018.

D. Garcia-borreguero, The long-term treatment of restless legs syndrome/Willis-Ekbom disease: Evidence-based guidelines and clinical consensus best practice guidance: A report from the International Restless Legs Syndrome Study Group, Sleep Med, vol.14, pp.675-684, 2013.

M. W. Hentze, M. U. Muckenthaler, B. Galy, and C. Camaschella, Two to Tango: Regulation of mammalian iron metabolism, Cell, vol.142, pp.24-38, 2010.

J. J. Kroot, H. Tjalsma, R. E. Fleming, and D. W. Swinkels, Hepcidin in human iron disorders: Diagnostic implications, Clin. Chem, vol.57, pp.1650-1669, 2011.

L. N. Van-der-vorm, Toward worldwide hepcidin assay harmonization: Identification of a commutable secondary reference material, Clin. Chem, vol.62, pp.993-1001, 2016.

E. Zipperer, Serum hepcidin measured with an improved ELISA correlates with parameters of iron metabolism in patients with myelodysplastic syndrome, Ann. Hematol, vol.92, pp.1617-1623, 2013.

A. T. Beck, R. A. Steer, and M. G. Carbin, Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation, Clin. Psychol. Rev, vol.8, pp.77-100, 1988.

M. W. Johns, A new method for measuring daytime sleepiness: The Epworth Sleepiness Scale, Sleep, vol.14, pp.540-545, 1991.

C. H. Bastien, A. Vallières, and C. M. Morin, Validation of the Insomnia Severity Index as an outcome measure for insomnia research, Sleep Med, vol.2, pp.297-307, 2001.

C. Iber, S. Ancoli-israel, A. L. Chesson, and S. F. Quan, The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications, Westchest Ill Am. Acad. Sleep Med, 2007.

M. Zucconi, The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG), Sleep Med, vol.7, pp.175-183, 2006.

C. Delaby, Clinical measurement of Hepcidin-25 in human serum: Is quantitative mass spectrometry up to the job?, EuPA Open Proteomics, vol.3, pp.60-67, 2014.

T. E. Galesloot, Serum hepcidin: Reference ranges and biochemical correlates in the general population, Blood, vol.117, pp.218-225, 2011.

B. Uelker, I. Cushman, T. Dudek, D. M. Herkert, and D. C. Geacintov, High sensitivity hepcidin-25 bioactive elisas: Manual and fully automated system for the quantification of hepcidin-25 in human serum and plasma, Blood, vol.128, pp.4820-4820, 2016.

G. Dahlfors, Validation of a competitive ELISA assay for the quantification of human serum hepcidin. Scand, J. Clin. Lab. Investig, vol.75, pp.652-658, 2015.

D. Girelli, E. Nemeth, and D. W. Swinkels, Hepcidin in the diagnosis of iron disorders, Blood, vol.127, pp.2809-2813, 2016.

N. Martinelli, Increased serum hepcidin levels in subjects with the metabolic syndrome: A population study, PLoS ONE, vol.7, p.48250, 2012.

J. L. Sullivan, Macrophage iron, hepcidin, and atherosclerotic plaque stability, Exp. Biol. Med, vol.232, pp.1014-1020, 2007.

T. E. Galesloot, Iron and hepcidin as risk factors in atherosclerosis: What do the genes say?, BMC Genet, vol.16, p.79, 2015.

, Scientific RepoRtS |, vol.10, 2020.

E. Nemeth, IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin, J. Clin. Investig, vol.113, pp.1271-1276, 2004.

G. Nicolas, The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation, J. Clin. Investig, vol.110, pp.1037-1044, 2002.

M. Wagner and D. Ashby, Hepcidin-a well-known iron biomarker with prognostic implications in chronic kidney disease, Nephrol. Dial. Transplant, vol.28, pp.2936-2939, 2013.

N. C. Van-der-weerd, Hepcidin-25 is related to cardiovascular events in chronic haemodialysis patients, Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. Eur. Ren. Assoc, vol.28, pp.3062-3071, 2013.

T. B. Grammer, Iron metabolism, hepcidin, and mortality (the Ludwigshafen Risk and Cardiovascular Health Study), Clin. Chem, vol.65, issue.7, pp.849-861, 2019.